Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.71 |
| ▸ | HTT | P42858 | 2/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6486442 | 0.84 | RAB9A (0.71) | L3MBTL1HTTNPC1CYP1A2CYP3A4 | |
| SCHEMBL11133805 | 0.84 | L3MBTL1 (0.78) | L3MBTL1HTTNPC1CYP1A2CYP3A4 | |
| SCHEMBL7822750 | 0.83 | HTT (1.00) | L3MBTL1HTTNPC1CYP1A2CYP3A4 | |
| SCHEMBL11133800 | 0.83 | L3MBTL1 (0.76) | L3MBTL1HTTNPC1CYP1A2CYP3A4 | |
| SCHEMBL11133813 | 0.83 | L3MBTL1 (0.76) | L3MBTL1HTTNPC1CYP1A2CYP3A4 | |
| SCHEMBL7018990 | 0.82 | L3MBTL1 (0.53) | L3MBTL1HTTNPC1CYP1A2CYP3A4 | |
| SCHEMBL7018985 | 0.82 | L3MBTL1 (0.53) | L3MBTL1HTTNPC1CYP1A2CYP3A4 | |
| SCHEMBL7440654 | 0.80 | L3MBTL1 (0.73) | L3MBTL1HTTNPC1CYP1A2CYP3A4 | |
| SCHEMBL11165745 | 0.78 | L3MBTL1 (0.68) | L3MBTL1HTTNPC1CYP1A2CYP3A4 | |
| SCHEMBL4230610 | 0.76 | L3MBTL1 (0.65) | L3MBTL1HTTNPC1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1252150-B1 | HETEROCYCLIC DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2003-06-04 | — | — | EP | claimed |
| US-20030040533-A1 | Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2003-02-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040533-A1 | Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same | CYP2F1, CYP11B2, CYP4B1 | L3MBTL1 4870/4885HTT 2340/4885NPC1 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.